0GQU Stock Overview
A biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Active Biotech AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.01 |
| 52 Week High | SEK 1.25 |
| 52 Week Low | SEK 1.01 |
| Beta | 0.53 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -66.10% |
| Change since IPO | -98.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GQU | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | n/a | -18.3% | 8.0% |
Return vs Industry: Insufficient data to determine how 0GQU performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0GQU performed against the UK Market.
Price Volatility
| 0GQU volatility | |
|---|---|
| 0GQU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0GQU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0GQU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 9 | Helen Tuvesson | www.activebiotech.com |
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.
Active Biotech AB (publ) Fundamentals Summary
| 0GQU fundamental statistics | |
|---|---|
| Market cap | SEK 250.32m |
| Earnings (TTM) | -SEK 58.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs 0GQU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GQU income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 58.40m |
| Earnings | -SEK 58.40m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 04, 2023
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0GQU perform over the long term?
See historical performance and comparison